Active Surveillance Up in Multidisciplinary Prostate CA Care

Share this article:
Active Surveillance Up in Multidisciplinary Prostate CA Care
Active Surveillance Up in Multidisciplinary Prostate CA Care

(HealthDay News) -- Men with low-risk prostate cancer are more likely to pursue active surveillance when seen at a multidisciplinary prostate cancer clinic rather than when they see individual specialists in sequential settings, according to a study published online July 30 in the Journal of Clinical Oncology.

To examine the factors associated with active surveillance in patients with low-risk prostate cancer, Ayal A. Aizer, M.D., M.H.S., of Massachusetts General Hospital in Boston, and colleagues conducted a study involving 701 men who were either treated at a multidisciplinary prostate cancer clinic with a team consisting of an urologist and radiation and medical oncologists, or who saw individual specialists sequentially.

The researchers found the crude rates of active surveillance to be almost double for those seen in the multidisciplinary clinic compared with those seen by individual physicians (43 versus 22 percent), while the proportion treated with prostatectomy or radiation therapy was reduced by about 30 percent. The pursuit of active surveillance was significantly associated with consultation at a multidisciplinary clinic (odds ratio [OR], 2.15), older age (OR, 1.09), unmarried status (OR, 1.66), increased Charlson comorbidity index (OR, 1.37), and fewer positive cores (OR, 0.92).

"In conclusion, our study indicates that multidisciplinary care is associated with a significantly increased rate of active surveillance in men with low-risk prostate cancer, a finding that may have an important clinical, social, and economic impact," the authors write.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Daily Oncology News

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

ACCR: Oral olaparib with chemotherapy beneficial for ovarian cancer

ACCR: Oral olaparib with chemotherapy beneficial for ovarian ...

Olaparib has been deemed safe in combination with carboplatin/paclitaxel in advanced ovarian cancer.

Meta-Analysis: Prediabetes tied to increased risk of cancer

Meta-Analysis: Prediabetes tied to increased risk of cancer

Prediabetes has been linked to an increased risk of cancer overall and with increased risks of site-specific cancers, including liver, endometrial, and stomach/colorectal cancer.

Joint ASCO/CCO guidelines for advanced prostate cancer issued

Joint ASCO/CCO guidelines for advanced prostate cancer issued

Recommendations are for men whose tumors have grown resistant to hormonal therapies were issued jointly by the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) in Canada.